14 Nov 9-month 2024 Key Financial Figures 21.2% increase in adjusted EBITDA from continuing operations
Paiania, 14 November 2024 – Lavipharm S.A. reports key consolidated financial figures of the first nine months of 2024.
An increase of 21.2% was posted on the Group’s adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations for the first nine months of 2024, which reached EUR 9.08 million, up from EUR 7.55 million during the corresponding period of the previous year. Accordingly, ….